Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
The most advanced candidate vaccine for malaria has cleared another major hurdle and is now ready for its last and biggest test: a phase III trial of 12,000 to 16,000 children at 11 locations in seven African countries.